Olympus has released PSA and fPSA assays for the Olympus AU3000i immunoassay analyser. The assays feature assay sensitivity of 0.015 µg/L. In the monitoring of patients after prostate cancer treatment, the sensitive PSA assay is suitable for the detection of recurrence of the disease.
The assays use a two-step immunometric design, minimising the risk of high-dose-hook and ensuring that the measurement of samples with elevated PSA levels will generate appropriate results. No high-dose-hook has been observed at PSA concentrations up to 160,000 µg/L, according to Olympus.
Other available test panels for the AU30001 include the primary tumour marker panel (AFP, CEA, PSA and fPSA) and the specialist tumour markers GI TN-TC and BR-TC.
Phone: 03 9265 5400
Beckman Coulter Life Sciences Basophil Activation Test (BAT) for food allergy research
Beckman Coulter Life Sciences introduces its next-generation Basophil Activation Test (BAT) to...
TopoGEN Topoisomerase Assay Kits
TopoGEN provides innovative reagents and kits for topoisomerase research and mechanism-based drug...
Alamar Biosciences NULISAseq Mouse Panel 120 for protein biomarker analysis
The multiplex panel encompasses a wide selection of proteins essential for studying key...
